Skip to content
Specimen Atlas of Research Peptides30 plates · MIT
PeptidesDBan atlas
← CataloguePlate XX of XXX
XXPlate XXReviewed 2026-04-25

Selank

Heptapeptide bioregulator

also known as Selanc, Selankum, TP-7

Synthetic 7-amino-acid peptide developed at the Russian Academy of Medical Sciences from the immunomodulator tuftsin. Demonstrates anxiolytic effects comparable to benzodiazepines but without sedation, cognitive impairment, or dependency. Acts via modulation of monoamine neurotransmission and the immune-CNS axis. Licensed in Russia + Ukraine; not approved elsewhere.

§ I

At a glance

Intranasal
150–300 mcg/dose
[zaderej-2014]
Mechanistic
Human
[zaderej-2014][medvedev-2007]
Onset
~30 min
Route

Intranasal · 2–3×/day during stress / cognitive demand

§ II

Mechanism

Primary target — Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domain [zaderej-2014].

Pathway — Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognition [medvedev-2007].

Downstream effect — Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γ [medvedev-2007][zaderej-2014].

Origin — Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide) [zaderej-2014].

Feedback intact — No GABA-receptor binding; no dependence reported [medvedev-2007].

§ III

Dosage

Protocols described in the cited literature; not medical advice.

ParameterValue
Standard dose150–300 mcg / dose intranasal [zaderej-2014]
Frequency2–3× per day during stress
Lower / starter dose75 mcg / dose
Evidence basisHuman-mechanistic + Russian clinical trials [medvedev-2007]
Duration10–14 day cycles, repeated as needed
ReconstitutionPre-formulated nasal spray (commercial); research vial: bacteriostatic water
TimingMorning + early afternoon preferred
Half-lifeShort (minutes plasma); CNS effect lasts ~3 hr
§ III · b

Reconstitution

A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.

Inputs
The calculator does pure mass-to-volume math. It does not recommend a dose. Refer to Selank's cited literature for protocol specifics.
Volumetric outputFig. C — reconstitution math
Volume per dose
0.100mL
≈ 10.0 units on a U-100 insulin syringe
Concentration
2500
mcg per mL
Doses per vial
20
at this dose
§ V

Adverse events

Severities follow the FDA / CTCAE convention.

Nasal irritationmild
Mild burning or congestion (transient)
Sedationmild
None — distinct from benzodiazepines [medvedev-2007]
Dependence / withdrawalmild
None reported in clinical use [zaderej-2014]
Cognitive impairmentmild
None — opposite effect (enhancement)
Allergic reactionmild
Rare hypersensitivity
Long-term safetymoderate
Limited Western RCT data
Pregnancy / OBsevere
Avoid — insufficient data
Absolute contraindications
  • — Pregnancy / breastfeeding
  • — Hypersensitivity to peptide
Relative contraindications
  • — Active autoimmune disease (theoretical via immunomodulation)
§ VI

Administration

  1. 01
    Form

    Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

  2. 02
    Administration

    Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

  3. 03
    Timing

    Morning + early afternoon for cognitive demand; PRN for acute anxiety.

  4. 04
    Storage

    Refrigerate after reconstitution; ≤30 days. Light-protected.

  5. 05
    Caveat

    Avoid co-administration with strong sedatives or other anxiolytics initially.

Appendix

Sources

28%

of 40 rendered claims carry a resolvable citation.

  1. [medvedev-2007]
    Medvedev 2007 — Pharmacology of Selank — anti-anxiety + cognitive effects
    Eksp Klin Farmakol, 2007
    PubMed →
  2. [zaderej-2014]
    Zaderej 2014 — Selank: anxiolytic effects + immunomodulation
    Bull Exp Biol Med, 2014
    Source →
Plate composed 2026-04-25 · maturity draft · schema v1 · Contributors: peptidesdb-core · 29 fields uncited — open contributions
Edit on GitHub →Read another →